NCT00700102 · STUDY IN CONTEXT

A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found because this study's registry identifier is printed in an FDA approval notice, an FDA product label or an NCI summary held by this site. The citing document and the exact position of the identifier inside it are recorded. Being cited is not a statement that the study supports this treatment.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Overall Survival: Time From Randomization to Death From Any Cause

Intention to treat

→

secondary · POSTED

Overall Survival: Months From Time of First Line Therapy

Source null

→

secondary · POSTED

Participants With Progression Free Survival Event

Unstratified intention to treat population

→

secondary · POSTED

Progression Free Survival: Time to Event

Unstratified intention to treat population

→

secondary · POSTED

Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria

Participants with measurable disease

→

secondary · POSTED

Response Evaluation Criteria In Solid Tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.

Participants with measurable disease

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-colorectal-neoplasm
nct id: NCT00700102
trial label: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: regulator-cited
discovery note: Found because this study's registry identifier is printed in an FDA approval notice, an FDA product label or an NCI summary held by this site. The citing document and the exact position of the identifier inside it are recorded. Being cited is not a statement that the study supports this treatment.
outcome Count: 6
harms Count: 2
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0000
source section id
NCT00700102-om-0000
source outcome index
0
endpoint
Overall Survival: Time From Randomization to Death From Any Cause
endpoint definition
Overall Survival: Time From Randomization to Death From Any Cause
time origin
within 6.5 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Intention to treat
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0001
source section id
NCT00700102-om-0001
source outcome index
1
endpoint
Overall Survival: Months From Time of First Line Therapy
endpoint definition
Overall Survival: Months From Time of First Line Therapy
time origin
within approximately 9.6 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0002
source section id
NCT00700102-om-0002
source outcome index
2
endpoint
Participants With Progression Free Survival Event
endpoint definition
Participants With Progression Free Survival Event
time origin
within 6.5 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Unstratified intention to treat population
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0003
source section id
NCT00700102-om-0003
source outcome index
3
endpoint
Progression Free Survival: Time to Event
endpoint definition
Progression Free Survival: Time to Event
time origin
within 6.5 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Unstratified intention to treat population
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0004
source section id
NCT00700102-om-0004
source outcome index
4
endpoint
Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria
endpoint definition
Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria
time origin
within 6.5 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Participants with measurable disease
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0005
source section id
NCT00700102-om-0005
source outcome index
5
endpoint
Response Rate: Participants With Response Status Based on RECIST Criteria
endpoint definition
Response Evaluation Criteria In Solid Tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.
time origin
within 6.5 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Participants with measurable disease
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0000
arm key
OG000
arm label
Chemotherapy
regimen
Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
analyzed count
410
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0000
arm key
OG001
arm label
Chemotherapy + Bevacizumab
regimen
Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
analyzed count
409
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0001
arm key
OG000
arm label
Chemotherapy
regimen
Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
analyzed count
410
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0001
arm key
OG001
arm label
Chemotherapy + Bevacizumab
regimen
Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
analyzed count
409
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0001#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0002
arm key
OG000
arm label
Chemotherapy
regimen
Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
analyzed count
410
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0002
arm key
OG001
arm label
Chemotherapy + Bevacizumab
regimen
Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
analyzed count
409
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0002#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0003
arm key
OG000
arm label
Chemotherapy
regimen
Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
analyzed count
410
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0003
arm key
OG001
arm label
Chemotherapy + Bevacizumab
regimen
Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
analyzed count
409
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0003#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0004
arm key
OG000
arm label
Chemotherapy
regimen
Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
analyzed count
406
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0004#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0004
arm key
OG001
arm label
Chemotherapy + Bevacizumab
regimen
Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
analyzed count
404
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0004#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0005
arm key
OG000
arm label
Chemotherapy
regimen
Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
analyzed count
406
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0005#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
outcome key
om-0005
arm key
OG001
arm label
Chemotherapy + Bevacizumab
regimen
Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
analyzed count
404
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700102-om-0005#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
harm key
EG000
source section id
NCT00700102-ae
event group key
EG000
event group label
Chemotherapy
serious affected
137
serious at risk
409
other affected
379
other at risk
409
frequency threshold
5
collection period
First subject first visit to end of trial within 7.25 years
event definition
Safety Analysis Set was defined as all randomized patients who received any amount of study treatment, and were analyzed according to actual treatment received.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-colorectal-neoplasm
nct id
NCT00700102
harm key
EG001
source section id
NCT00700102-ae
event group key
EG001
event group label
Chemotherapy + Bevacizumab
serious affected
130
serious at risk
401
other affected
382
other at risk
401
frequency threshold
5
collection period
First subject first visit to end of trial within 7.25 years
event definition
Safety Analysis Set was defined as all randomized patients who received any amount of study treatment, and were analyzed according to actual treatment received.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice